カテゴリ： GlobalData, アメリカ, 企業調査

Provectus Biopharmaceuticals Inc (PVCT)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Provectus Biopharmaceuticals Inc (PVCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013618
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：57
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Provectus Biopharmaceuticals Inc (Provectus), formerly Provectus pharmaceuticals Inc is a biotechnology company that develops pharmaceuticals for oncology and dermatology indications. The company provides pipeline products such as PV-10 for recurrent melanoma, PV-10 for metastatic liver cancer and PV-10 for recurrent breast cancer. It offers PH-10 for psoriasis and PH-10 for atopic dermatitis. Provectus conducts research on ongoing clinical trials for indications including breast cancers, melanoma, basal cell carcinoma and squamous cell carcinoma. The company also offers programs and experimental therapeutic in hospitals and institutes in Bethlehem, Houston, Louisville, San Diego, Sydney, Brisbane and Adelaide, among others. Provectus is headquartered in Knoxville, Tennessee, the US.

Provectus Biopharmaceuticals Inc (PVCT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Provectus Biopharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Provectus Biopharma Enters into Research Agreement with POETIC 12
Licensing Agreements 13
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 13
Equity Offering 15
Provectus Biopharma Raises USD6 Million in Public Offering of Series B Preferred Stock and Warrants 15
Provectus Biopharma Raises USD13.1 Million in Public Offering of Shares and Warrants 17
Provectus Pharma Announces Private Placement Of Shares For Up To US$30 Million 19
Provectus Pharma Completes Private Placement Of Units For US$2 Million 20
Provectus Pharma Completes Private Placement Of Units For US$2.1 Million 21
Provectus Pharma And Its Subsidiaries Complete Private Placement Of Units For US$2.5 Million 22
Provectus Pharma Files Registration Statement For A Public Offering For US$50 Million 23
Provectus Pharma Completes Registered Direct Offering Of US$5.1 Million 24
Provectus Biopharmaceuticals Inc – Key Competitors 26
Provectus Biopharmaceuticals Inc – Key Employees 27
Provectus Biopharmaceuticals Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 10, 2016: Provectus Biopharmaceuticals Reports Third Quarter 2016 Financial Results 29
Aug 09, 2016: Provectus Biopharmaceuticals Reports Second Quarter 2016 Financial Results 30
May 10, 2016: Provectus Biopharmaceuticals Reports First Quarter 2016 Financial Results 31
Mar 30, 2016: Provectus Biopharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results 32
Corporate Communications 33
Apr 20, 2017: Provectus Biopharmaceuticals Reestablishes Strategic Advisory Board 33
Feb 23, 2017: Provectus Biopharmaceuticals Appoints Bruce Horowitz And Dominic Rodrigues As Special Advisers To The Board Of Directors 34
Dec 28, 2016: Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO 35
Nov 30, 2016: Provectus Biopharmaceuticals Announces Notification of NYSE MKT Listing Deficiency 36
Feb 29, 2016: Provectus Biopharmaceuticals Announces Leadership Changes 37
Legal and Regulatory 38
Mar 16, 2016: Provectus Announces Results of Internal Investigation 38
Product News 39
08/01/2016: Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 for Melanoma at European Society for Medical Oncology 2016 Congress 39
07/14/2016: Provectus Biopharmaceuticals Establishes Australian Subsidiary 40
07/12/2016: Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at European Society for Medical Oncology 2016 Congress 41
06/09/2016: Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Annual Meeting of American Society of Clinical Oncology Now Available Online 42
06/07/2016: Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology 43
05/19/2016: Provectus Biopharmaceuticals Announces Abstract Available Online of Trials in Progress; Abstract for Poster Presentation at ASCO Annual Meeting 44
05/13/2016: Provectus Biopharmaceuticals Announces Publication of Article in Oncotarget Detailing PV-10’s Immuno-Ablative Mechanism of Action 45
04/28/2016: Provectus Biopharmaceuticals Announces Publication of Two Abstracts on Research into IL PV-10 for Melanoma in Special Issue of ANZ Journal of Surgery 46
04/22/2016: Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at American Association for Cancer Research (AACR) Annual Meeting 2016 47
03/18/2016: Provectus Biopharmaceuticals Announces Abstract Publicly Available for Poster Presentation on PV-10 in Combination Therapy and T Cell Mediated Immunity 48
02/24/2016: Provectus Biopharmaceuticals Announces Data on PV-10 and Co-Inhibitory Blockade to Be Presented at American Association for Cancer Research Annual Meeting 2016 49
02/03/2016: Data on Immunology Effects of Provectus Biopharmaceuticals PV-10 in Colon Cancer Presented at 11th Annual ASC Meeting 50
01/22/2016: Provectus Biopharmaceuticals Announces Immunology Data on PV-10 in Colon Cancer to Be Presented at 11th Annual ASC Meeting 51
Clinical Trials 52
Jul 13, 2016: Provectus Biopharmaceuticals Announces PV-10 Data Discussed at 6th European Post-Chicago Melanoma/Skin Cancer Meeting 52
May 19, 2016: Provectus Biopharmaceuticals Announces Abstract Available on PV-10 Plus Radiotherapy in Melanoma 53
Mar 16, 2016: Provectus Biopharmaceuticals Amends Protocol for Phase 3 Study of PV-10 in Treatment of Locally Advanced Cutaneous Melanoma 54
Feb 29, 2016: Provectus Biopharmaceuticals Initiating Phase I Study of PV-10 in Neuroendicrine Tumors Metastatic to Liver 55
Jan 12, 2016: Provectus Biopharmaceuticals Confirms First Patients Dosed in Phase 3 Trial of PV-10 for Melanoma 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Provectus Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Provectus Biopharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Provectus Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Provectus Biopharma Enters into Research Agreement with POETIC 12
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 13
Provectus Biopharma Raises USD6 Million in Public Offering of Series B Preferred Stock and Warrants 15
Provectus Biopharma Raises USD13.1 Million in Public Offering of Shares and Warrants 17
Provectus Pharma Announces Private Placement Of Shares For Up To US$30 Million 19
Provectus Pharma Completes Private Placement Of Units For US$2 Million 20
Provectus Pharma Completes Private Placement Of Units For US$2.1 Million 21
Provectus Pharma And Its Subsidiaries Complete Private Placement Of Units For US$2.5 Million 22
Provectus Pharma Files Registration Statement For A Public Offering For US$50 Million 23
Provectus Pharma Completes Registered Direct Offering Of US$5.1 Million 24
Provectus Biopharmaceuticals Inc, Key Competitors 26
Provectus Biopharmaceuticals Inc, Key Employees 27
Provectus Biopharmaceuticals Inc, Subsidiaries 28

★海外企業調査レポート[Provectus Biopharmaceuticals Inc (PVCT)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Kawasaki Heavy Industries Ltd (7012)：企業の財務・戦略的SWOT分析
    Kawasaki Heavy Industries Ltd (7012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Helomics Corp-製薬・医療分野：企業M&A・提携分析
    Summary Helomics Corp(Helomics) is a life science company that develops and offers precision medicine support tools and services for cancer treatment. The company’s products include chemofx, biospecifx, genefx colon and genefx lung. Its chemofx is a drug response marker, which is used to test tumor …
  • InDex Pharmaceuticals Holding AB (INDEX)：企業の財務・戦略的SWOT分析
    Summary InDex Pharmaceuticals Holding AB (InDex Pharmaceuticals) is a pharmaceutical company that offers treatments for immunological diseases. The company’s lead compound cobitolimod, currently in the phase 2 stage, is intended for the treatment of moderate to severe treatment active refractory ulc …
  • Ecobee Inc：電力：M&Aディール及び事業提携情報
    Summary Ecobee Inc (Ecobee) is a thermostat device provider. The company offers ecobee swith plus, ecobee four, ecobee four smarter bundle, ecobee three lite, ecobee three lite smarter bundle, refurbished ecobee three, EMS Si and room sensors. Its products are controlled through voice control and mo …
  • Enerjisa Enerji Uretim AS：電力：M&Aディール及び事業提携情報
    Summary Enerjisa Enerji Uretim A.S. (Enerjisa Enerji), a subsidiary of Enerjisa Enerji A.S, is an energy utility. The company generates electricity from natural gas, lignite coal, hydro, and wind sources. It owns and operates wind plants such as Canakkale in Mahmudiye, Dagpazari in Mut, and Balikesi …
  • Kiewit Corporation：企業の戦略・SWOT・財務情報
    Kiewit Corporation - Strategy, SWOT and Corporate Finance Report Summary Kiewit Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Polydex Pharmaceuticals Ltd (POLXF)：企業の財務・戦略的SWOT分析
    Summary Polydex Pharmaceuticals Ltd (PPL) is a manufacturer and marketer of pharmaceutical intermediates for human and veterinary pharmaceutical markets. The company manufactures and sells bulk quantities of dextran and derivative products. Its dextran and its derivatives can be used as adjuvants, e …
  • Dana Petroleum Ltd：企業の戦略的SWOT分析
    Dana Petroleum Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Emera (Caribbean) Inc.：発電所・企業SWOT分析
    Emera (Caribbean) Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employ …
  • KemPharm Inc (KMPH)：製薬・医療：M&Aディール及び事業提携情報
    Summary KemPharm Inc (KemPharm) is a clinical-stage specialty pharmaceutical company that offers discovery and development of proprietary new molecular entity prodrugs. The company’s product pipeline includes KP415, methylphenidate drug for ADHD; KP201/IR, KP511/ER, KP606/IR and KP746 drugs for the …
  • Bial – Portela & Ca SA：製薬・医療：M&Aディール及び事業提携情報
    Summary Bial - Portela & Ca SA (BIAL) is a pharmaceutical company that discovers, develops and provides drugs for neurosciences and cardiovascular therapeutic areas. The company offers products such as anti-inflammatories, anti-diabetics, cardiovascular, anti-asthmatics, antibiotics, antidepressants …
  • Nippon Flour Mills Co., Ltd.
    Nippon Flour Mills Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Flour Mills Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Hindustan Construction Co Ltd (HCC)：企業の財務・戦略的SWOT分析
    Hindustan Construction Co Ltd (HCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Danaher Corp (DHR)：医療機器：M&Aディール及び事業提携情報
    Summary Danaher Corp (Danaher) is a medical technology company which designs, manufactures and markets medical, professional, commercial and industrial products and services. It offers a wide range of testing instruments, communications solutions, water quality systems, medical diagnostics solutions …
  • Orange Polska S.A.：戦略・SWOT・企業財務分析
    Orange Polska S.A. - Strategy, SWOT and Corporate Finance Report Summary Orange Polska S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mitobridge Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Mitobridge Inc (Mitobridge), formerly Mitokyne Inc, a subsidiary of Astellas Pharma Inc is a drug development company that discovers and develops small molecule therapeutics that recovers mitochondrial functions. The company develops therapies for rare diseases and expands into more common d …
  • Travis Perkins plc：企業の戦略・SWOT・財務分析
    Travis Perkins plc - Strategy, SWOT and Corporate Finance Report Summary Travis Perkins plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • N.V. Nationale Borg-Maatschappij：企業の戦略・SWOT・財務情報
    N.V. Nationale Borg-Maatschappij - Strategy, SWOT and Corporate Finance Report Summary N.V. Nationale Borg-Maatschappij - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Shanghai Pudong Development Bank Co., Ltd.：戦略・SWOT・企業財務分析
    Shanghai Pudong Development Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shanghai Pudong Development Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Genesee BioMedical Inc-医療機器分野：企業M&A・提携分析
    Summary Genesee BioMedical Inc (Genesee BioMedical) is a medical device company that provides medical and surgical instruments. The company’s products include coronary bypass graft markers, pediatric and adult cardiac surgical instruments, off-pump CABG devices, adult thoracic retractors, and cardia …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆